MEDIANTECHNOLOGIES (ALMDT)

MEDIAN TECHNOLOGIES

Sell: €3.165|Buy: €3.29|Change: 0.04 (-1.08%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

€3.25

Previous close

€3.24

Trade high

€3.29

Volume

138,798

Year high

€5.26

Year low

€1.192

Dividend yield

–

Market capitalisation

€116.01 mn

P/E ratio

–

ISIN

FR0011049824

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Performance 21/10/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
MEDIANTECHNOLOGIES	- 1.08
More...

Company profile

Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The firm intends to target the oncology clinical trials market and the cancer patient care market. It developed software-based tools that are integrated into a clinical application portfolio called Lesion Management Solutions. The company has two platforms, iSee for imaging services inclinical trials and eyonis for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer and other chronic diseases. Geographically, the company generates revenue from EMEA, the USA/Canada, and China.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.